DGAP-News

Sangui BioTech International files S-1 Registration Statement with the SEC

DGAP-News: Sangui BioTech International Inc. / Key word(s): Financing
Sangui BioTech International files S-1 Registration Statement with the
SEC

26.06.2015 / 13:00

---------------------------------------------------------------------

Sangui BioTech International files S-1 Registration Statement with the SEC

Prerequisite for drawing upon financial framework agreement with US
investor of $5 million

Witten, Germany, June 26, 2015 - Sangui Biotech International, Inc. has
filed a preliminary S-1 Registration Statement with the Securities and
Exchange Commission. It is being expected that the SEC will declare the
Prospectus effective within the next couple of weeks. The exact timeline
depends on SEC approval procedures which cannot be anticipated by the
company. The S-1 becoming effective is prerequisite for Sangui to start
drawing upon the financial framework agreement with US investor Southridge
as announced on May 12, 2015.

Under the terms of this agreement Sangui Biotech International, Inc.
acquired the right to sell shares to a fund of Southridge LLC, an
institutional investor, located in Connecticut and New York in the amount
of up to $5 million over a period of three years.

This financial instrument is one element of Sangui's plan to carry out the
preclinical phase of its SBT102 product which underwent successful
preclinical testing. SBT102 developed by SanguiBioTech improves the oxygen
supply of vital organs. It's intraperitoneal application is an innovative
and effective therapy to avoid tissue hypoxemia in cases of septic shock.
It can be expected that the restoration of intestinal oxygenation will have
an impact on tissue integrity and eventually on patient survival.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.



---------------------------------------------------------------------

26.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


372461 26.06.2015